Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | AR | P10275 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810828 | 0.98 | KDM4E (0.53) | KDM4EARKMT2ACYP19A1RAB9A | |
| Bromide SCHEMBL3837111 | 0.96 | KDM4E (0.52) | KDM4EARKMT2ACYP19A1RAB9A | |
| SCHEMBL178051 | 0.81 | ALDH1A1 (0.61) | KDM4EARKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL9361283 | 0.78 | LTA4H (0.63) | KDM4EKMT2ACYP19A1RAB9ASMN1; SMN2 | |
| SCHEMBL3185335 | 0.78 | RAB9A (0.56) | KDM4EKMT2ACYP19A1RAB9ASMN1; SMN2 | |
| SCHEMBL6174249 | 0.78 | RAB9A (0.61) | KDM4EKMT2ACYP19A1RAB9ASMN1; SMN2 | |
| SCHEMBL1807468 | 0.77 | CYP19A1 (0.67) | KDM4EKMT2ACYP19A1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL14764903 | 0.77 | PABPC1 (0.46) | KDM4EARKMT2ACYP19A1RAB9A | |
| SCHEMBL4183399 | 0.77 | LTA4H (0.56) | KDM4EARKMT2ARAB9AMAPT | |
| SCHEMBL1984060 | 0.75 | PABPC1 (0.42) | KDM4EKMT2ARAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104725425-A | Preparation method for ceftaroline fosamil | SHANDONG LUOXIN PHARMACEUTICAL GROUP CO LTD | 2015-06-24 | — | — | CN | claimed |
| WO-2016128580-A1 | CEPHALOSPORIN INTERMEDIATE AND PROCESS FOR ITS PREPARATION | FRESENIUS KABI ANTI-INFECTIVES SRL (IT) | 2016-08-18 | — | — | WO | disclosed |
| CN-104725425-A | Preparation method for ceftaroline fosamil | SHANDONG LUOXIN PHARMACEUTICAL GROUP CO LTD | 2015-06-24 | — | — | CN | disclosed |
| CN-104725425-A | Preparation method for ceftaroline fosamil | SHANDONG LUOXIN PHARMACEUTICAL GROUP CO LTD | 2015-06-24 | — | — | CN | disclosed |
| EP-1310502-B1 | PHOSPHONOCEPHEM COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2009-05-20 | — | — | EP | disclosed |
| EP-2020416-A1 | Phosphonocephem compound | Takeda Pharmaceutical Company Limited (JP) | 2009-02-04 | — | — | EP | disclosed |
| US-7419973-B2 | crystal of 3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-7 beta -[2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetamido]-3-cephem-4-carboxylate with acetic acid and water (Ceftaroline fosamil acetate solvate), crystals; MRSA infections; storage stability, high purity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-02 | — | — | US | disclosed |
| US-20050176697-A1 | crystal of 3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-7 beta -[2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetamido]-3-cephem-4-carboxylate with acetic acid and water, crystals; anti-Methicillin Resistant Staphylococcus aureus agent; storage stability, high purity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6906055-B2 | Phosphonocephem compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| CN-1189471-C | Phosphonocephem compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-02-16 | — | — | CN | disclosed |
| US-20040023943-A1 | A cephem compound (particularly its crystal) represented by the formula (I), wherein X is CH3COOH, CH3CH2COOH or CH3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| CN-1462275-A | Phosphonocephem compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-12-17 | — | — | CN | disclosed |
| EP-1310502-A1 | PHOSPHONOCEPHEM COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176697-A1 | crystal of 3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-7 beta -[2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetamido]-3-cephem-4-carboxylate with acetic acid and water, crystals; anti-Methicillin Resistant Staphylococcus aureus agent; storage stability, high purity | CHAMP1, ACP1, SFN | KDM4E 797/4885AR 2170/4885KMT2A 1203/4885 |
| US-20040023943-A1 | A cephem compound (particularly its crystal) represented by the formula (I), wherein X is CH3COOH, CH3CH2COOH or CH3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such | CEP170, CORO1C, CALCOCO2 | KDM4E 1562/4885AR 3705/4885KMT2A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.